RAPT Therapeutics develops oral small-molecule therapeutics that modulate immune responses for oncology and inflammatory diseases using a proprietary discovery and development engine. The company’s lead oncology candidate, FLX475, is in clinical development targeting multiple cancers, and its lead inflammation candidate, RPT193 was expected to enter the clinic in the second half of 2019. Management expected proof-of-concept results in the first half of 2020 for FLX475 and in mid-2020 for RPT193 in atopic dermatitis. RAPT has rapidly discovered and advanced two unique CCR4-targeting drug candidates and is pursuing additional discovery targets including GCN2 and HPK1. The company is based in South San Francisco, Calif., and has been advancing its pipeline toward clinical readouts. FLX Bio is focused on discovery and development of orally-available small-molecule immuno-oncology drugs that target regulatory T cells and myeloid cells within the tumor microenvironment. Its lead candidate, FLX475, is a best-in-class oral CCR4 antagonist that the company has advanced into Phase 1 studies and recently dosed the first subject. FLX475 showed tumor growth inhibition and enhanced activity with checkpoint inhibitors in preclinical studies, and FLX Bio plans clinical testing alone and in combination with checkpoint inhibitors. The company is also advancing programs against USP7 and GCN2, intending to select a USP7 clinical candidate in late 2018 and continue its GCN2 program. FLX Bio applies computational and translational biology for prospective patient selection and biomarker-driven precision medicine. The company is located in South San Francisco, Calif. FLX Bio is a South San Francisco, CA–based biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Its pipeline includes FLX925, a selective inhibitor of FLT3 and CDK4/6 currently in Phase 1. The company intends to use the Series B proceeds to advance its pipeline and to conduct a proof-of-concept study of FLX925 in patients with acute myeloid leukemia. FLX has raised a total of $79m to date, including the $50m Series B. Founded in 2015 by Brian Wong, M.D., Ph.D., the company originated from the acquisition of its predecessor Flexus Biosciences by Bristol-Myers Squibb. FLX says it has assembled a management and leadership team with substantial knowledge and expertise in the tumor microenvironment, drug discovery and translational areas.

Total raised

$147M

Funding rounds

3

Latest round

Series C

Latest activity

Jun 2019